AKT1 and neoplasm: Akt1/2 shRNA or doxorubicinslowed tumor growth by approximately 40–50% (Fig. 6B), while the combination of Akt1/2 shRNA anddoxorubicin inhibited growth by 74% without affecting body weight (Suppl.